Xencor (XNCR) Competitors $8.83 +0.39 (+4.62%) Closing price 04:00 PM EasternExtended Trading$8.94 +0.11 (+1.19%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. GMTX, ARWR, APLS, TWST, NAMS, APGE, RXRX, DNLI, INDV, and VCELShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Indivior (INDV), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience NewAmsterdam Pharma Apogee Therapeutics Recursion Pharmaceuticals Denali Therapeutics Indivior Vericel Xencor (NASDAQ:XNCR) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is XNCR or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -181.17%. Xencor's return on equity of -31.94% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xencor-181.17% -31.94% -22.19% Gemini Therapeutics N/A -38.78%-35.88% Which has higher valuation and earnings, XNCR or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than Xencor. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$127.23M4.94-$232.62M-$3.06-2.89Gemini TherapeuticsN/AN/A-$71.87M-$1.00-56.27 Which has more volatility and risk, XNCR or GMTX? Xencor has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Does the media prefer XNCR or GMTX? In the previous week, Xencor had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Xencor and 1 mentions for Gemini Therapeutics. Xencor's average media sentiment score of 0.76 beat Gemini Therapeutics' score of 0.00 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of XNCR or GMTX? 75.4% of Gemini Therapeutics shares are held by institutional investors. 5.2% of Xencor shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend XNCR or GMTX? Xencor currently has a consensus target price of $28.00, indicating a potential upside of 217.10%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryXencor beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$628.44M$2.44B$5.57B$9.31BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.899.1828.6119.73Price / Sales4.94575.37411.31174.27Price / CashN/A164.3436.0257.96Price / Book0.924.698.235.67Net Income-$232.62M$30.99M$3.23B$257.79M7 Day Performance-5.36%0.60%-0.01%0.52%1 Month Performance-2.43%7.93%5.60%8.84%1 Year Performance-56.78%-5.48%26.54%14.18% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor4.4087 of 5 stars$8.83+4.6%$28.00+217.1%-57.1%$628.44M$127.23M-2.89280GMTXGemini TherapeuticsN/A$54.75+3.0%N/A+22.4%$2.37BN/A-54.7530News CoverageARWRArrowhead Pharmaceuticals3.5639 of 5 stars$16.84+0.3%$43.71+159.6%-38.9%$2.32B$545.21M-12.03400News CoverageAPLSApellis Pharmaceuticals4.2287 of 5 stars$17.42-4.6%$39.79+128.4%-51.6%$2.29B$781.37M-9.73770News CoverageAnalyst ForecastAnalyst RevisionTWSTTwist Bioscience4.1794 of 5 stars$35.59-6.8%$50.40+41.6%-35.2%$2.29B$312.97M-10.95990NAMSNewAmsterdam Pharma2.7406 of 5 stars$19.46-2.0%$42.89+120.4%+7.3%$2.23B$47.14M-10.354APGEApogee Therapeutics3.0648 of 5 stars$39.24-17.3%$99.00+152.3%-24.8%$2.19BN/A-10.9091High Trading VolumeRXRXRecursion Pharmaceuticals1.8109 of 5 stars$4.93-6.5%$7.00+42.0%-36.3%$2.14B$58.84M-2.79400High Trading VolumeDNLIDenali Therapeutics4.6833 of 5 stars$14.25-3.0%$33.71+136.6%-39.3%$2.13B$330.53M-5.34430Positive NewsINDVIndivior1.1978 of 5 stars$15.55+0.9%$17.00+9.3%+47.9%$2.12B$1.17B-50.161,051VCELVericel3.6942 of 5 stars$39.41-5.6%$61.14+55.1%-25.6%$2.10B$237.22M1,314.10300News CoveragePositive News Related Companies and Tools Related Companies Gemini Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Twist Bioscience Alternatives NewAmsterdam Pharma Alternatives Apogee Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Denali Therapeutics Alternatives Indivior Alternatives Vericel Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
